Zeposia (Ozanimod) Demonstrates Long-Term Efficacy and Safety in MS Patients
New Long-Term Efficacy Data on Zeposia (Ozanimod)
Bristol Myers Squibb has revealed exciting findings from the Phase 3 DAYBREAK trial regarding Zeposia (Ozanimod). The study highlights durable efficacy and consistent safety in patients with relapsing forms of Multiple Sclerosis. The data indicates that participants experienced decreased rates of brain volume loss during the open-label extension (OLE), solidifying Zeposia as a promising therapeutic option.
Key Findings from the DAYBREAK Trial
- Long-term safety: Continuous monitoring through the OLE phases shows sustained efficacy.
- Low incidence of adverse effects: The trial confirms that Zeposia maintains a favorable safety profile.
- Comprehensive data collection: The trial systematically tracks progress in real-world settings.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.